期刊
ANNALES DE BIOLOGIE CLINIQUE
卷 76, 期 3, 页码 308-312出版社
JOHN LIBBEY EUROTEXT LTD
DOI: 10.1684/abc.2018.1325
关键词
procalcitonin; analytical performance; Abbott Diagnostics; Brahms
Procalcitonin (PCT) is a useful biomarker for the diagnosis of bacterial infection. Its measurement is used routinely as a valuable tool for antibiotic treatment decision. The aim of this study is to assess the analytical performance of the new Architect Brahms PCT (R) reagents on the Abbott Architect i2000-SR (R) immuno-analyzer. The Architect PCT (R) assay was evaluated according to the modified SFBC protocol, in accordance with the NF EN ISO 15189 standard. Sixty two samples from patients hospitalized in Necker Hospital (Paris) have been tested with the evaluated method, and results were compared to those of the PCT Kryptor Brahms (R) method. Analytical performances tested complied with those announced by the manufacturer. Linear regression showed a strong correlation between the two methods (r > 0.99), despite a tendency for overestimation by the new method (y=1.10 x + 0.05). Bland-Altman plots confirmed this strong correlation by showing only two points outside the acceptable limits without clinical incidence, given the high PCT concentrations (over 10 ng/mL) in those samples. In conclusion, the new PCT assay on the Abbott Architect i2000-SR (R) shows excellent analytical performances, even at low concentrations. A slight positive bias compared to the Brahms Kryptor (R) was observed, but did not lead to inappropriate clinical decisions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据